BiTEs may promote downregulation of their target antigen as a mechanism of immune escape, as evidenced by a metanalysis of ALL patients initially treated with blinatumomab exhibiting increased relapse after CAR T therapy and decreased event-free survival with a trend towards exhibiting more CD19 dim disease. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.